Last Updated : March 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
---|---|---|---|---|---|---|
Nucala | mepolizumab | Eosinophilic granulomatosis with polyangiitis | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Forxiga | dapagliflozin | Chronic kidney disease | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Emgality | galcanezumab | Episodic cluster headache | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Clolar | clofarabine | Acute lymphoblastic leukemia | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Breyanzi | lisocabtagene maraleucel | Relapsed or refractory large B-cell lymphoma | Pending | |||
TBC | fruquintinib | Metastatic colorectal cancer (mCRC) | Pending | |||
Onivyde | Nanoliposomal Irinotecan | Cancelled | ||||
Cyramza | Ramucirumab | Cancelled | ||||
Combigan Ophthalmic Solution | Brimonidine tartrate/timolol maleate | Glaucoma | List with clinical criteria and/or conditions | Complete | ||
Reyataz | Atazanavir | HIV infection | List in a similar manner to other drugs in class | Complete |